Effect of selective serotonin reuptake inhibitor discontinuation on anxiety-like behaviours in mice.

Pinacho R
Ozdemir D
Bannerman DM
Sharp T
Scientific Abstract

Abrupt cessation of therapy with a selective serotonin reuptake inhibitor (SSRI) is associated with a discontinuation syndrome, typified by numerous disabling symptoms, including anxiety. Surprisingly, little is known of the behavioural effect of SSRI discontinuation in animals.

Here, the effect of SSRI discontinuation on anxiety-like behaviour was systematically investigated in mice.

Experiments were based on a three-arm experimental design comprising saline, continued SSRI and discontinued SSRI. Mice were assessed 2 days after SSRI discontinuation over a 5-day period using the elevated plus maze (EPM) and other anxiety tests.

An exploratory experiment found cessation of paroxetine (12 days) was associated with decreased open-arm exploration and reduced total distance travelled, in male but not female mice. Follow-up studies confirmed a discontinuation effect on the EPM in male mice after paroxetine (12 days) and also citalopram (12 days). Mice receiving continued paroxetine (but not citalopram) also showed decreased open-arm exploration but this was dissociable from the effects of discontinuation. The discontinuation response to paroxetine did not strengthen after 28 days of treatment but was absent after 7 days of treatment. A discontinuation response was not discernible in other anxiety and fear-learning tests applied 3-5 days after treatment cessation. Finally, discontinuation effects on the EPM were typically associated with decreased locomotion on the test. However, separate locomotor testing implicated anxiety-provoked behavioural inhibition rather than a general reduction in motor activity.

Overall, this study provides evidence for a short-lasting behavioural discontinuation response to cessation of SSRI treatment in mice.

Citation

2022. J Psychopharmacol, 36(7):794-805.

DOI
10.1177/02698811221093032
Related Content
Publication
Author
Reeve HM
Koolschijn RS
Shpektor A
Nili H
Rothaermel R
Campo-Urriza N
O'Reilly JX
Bannerman DM
Behrens TE
2020. Cell, 183(1):228-243.e21.
Publication
Author
Torrecillos F
Mostofi A
Bange M
Hasegawa H
Glaser M
Muthuraman M
Groppa S
Ashkan K
Pereira EA

2020. J. Neurosci., 40(7):1571-1580.

Publication
Author
Pristerà A
Lin WY
Kaufmann AK
Brimblecombe KR
Threlfell S
Fernandes C
Cragg SJ
Ang SL
2015.Proc. Natl. Acad. Sci. U.S.A., 112(35):E4929-38.
Publication
Author
Cieślak PE
Ahn WY
Rodriguez Parkitna J
2018. eNeuro. 5(4):e0331-18.2018